ArticleBritish journal of cancer2026
Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Forty-month durable partial response with well-tolerated olaparib maintenance in a 92-year-old patient withGynecology and pelvic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHomologous recombination deficiency (HRD) has emerged as a functional biomarker reflecting genome-wide DNA repair defects and genomic instability. While the Cancer Genome Atlas (TCGA) molecular classification provides valuable prognostic guidance in endometrial cancer (EC), it lacks resolution for DNA repair competency and therapeutic responsiveness. This study aimed to investigate whether HRD subtyping could complement TCGA classification for improved prognostic stratification and therapeutic decision-making.
methodsA total of 142 EC patients were analysed using a next-generation sequencing panel and genomic scar-based HRD scoring (loss of heterozygosity, telomeric allelic imbalance, large-scale state transitions). Unsupervised clustering stratified patients into HRD-High, -Middle, and -Low groups. Maximally selected rank statistics were used to identify prognostic thresholds for HRD scores; the tumour-immune microenvironment was characterised by RNA-based immune gene expression profiling and multiplex immunohistochemistry. A support vector machine (SVM) model was developed for recurrence prediction.
resultsHRD subtyping identified distinct genomic, pathological, and immunological features. HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration. HRD subtyping independently predicted disease-free survival and showed superior prognostic accuracy (C-index = 0.857) compared to TCGA subtyping (C-index = 0.751). Integrating HRD and TCGA classifiers further improved predictive performance (C-index = 0.903). An SVM model incorporating HRD score and immune features achieved an AUC of 0.733 for recurrence prediction.
conclusionsHRD subtyping refines risk stratification beyond traditional TCGA classification and identifies patients potentially responsive to immune checkpoint or DNA damage-targeted therapies. Integrating HRD-based genomic instability metrics with molecular and immune profiling supports precision oncology in endometrial cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.